[go: up one dir, main page]

WO2006039268A3 - Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations - Google Patents

Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations Download PDF

Info

Publication number
WO2006039268A3
WO2006039268A3 PCT/US2005/034587 US2005034587W WO2006039268A3 WO 2006039268 A3 WO2006039268 A3 WO 2006039268A3 US 2005034587 W US2005034587 W US 2005034587W WO 2006039268 A3 WO2006039268 A3 WO 2006039268A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipophilic drugs
containing vitamin
formulations
efflux inhibition
pharmaceutical formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/034587
Other languages
French (fr)
Other versions
WO2006039268A2 (en
Inventor
John Anthony Hyatt
George Chester Zima
Kevin Joseph Edgar
Lisa Tonner Navarro
Claus-Michael Lehr
Eva-Maria Collnot
Andy Hugh Singleton
Christiane Baldes
Ulrich Friedrich Schafer
Michael Fitzpatrick Wempe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastman Chemical Co
Original Assignee
Eastman Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Chemical Co filed Critical Eastman Chemical Co
Priority to EP05803721A priority Critical patent/EP1793806A2/en
Priority to JP2007534708A priority patent/JP2008514714A/en
Publication of WO2006039268A2 publication Critical patent/WO2006039268A2/en
Publication of WO2006039268A3 publication Critical patent/WO2006039268A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compounds and compositions are disclosed for increasing the bioavailability of lipophilic drugs, and more specifically, to solubilizing lipophilic drugs using bioenhancers that cause no efflux inhibition or a desired degree of efflux inhibition. Methods of making and using such compositions are also disclosed.
PCT/US2005/034587 2004-09-30 2005-09-29 Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations Ceased WO2006039268A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05803721A EP1793806A2 (en) 2004-09-30 2005-09-29 Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
JP2007534708A JP2008514714A (en) 2004-09-30 2005-09-29 Pharmaceutical formulations containing vitamin ETPGS molecules solubilizing lipophilic drugs that do not exhibit significant spill inhibition and the use of such pharmaceutical formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61489104P 2004-09-30 2004-09-30
US60/614,891 2004-09-30

Publications (2)

Publication Number Publication Date
WO2006039268A2 WO2006039268A2 (en) 2006-04-13
WO2006039268A3 true WO2006039268A3 (en) 2006-07-27

Family

ID=36142996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034587 Ceased WO2006039268A2 (en) 2004-09-30 2005-09-29 Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations

Country Status (4)

Country Link
EP (1) EP1793806A2 (en)
JP (1) JP2008514714A (en)
CN (1) CN101031284A (en)
WO (1) WO2006039268A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240051A1 (en) * 2005-04-26 2006-10-26 Singleton Andy H Eutectic blends containing a water soluble vitamin derivative
AU2010216337B2 (en) 2009-02-23 2014-07-10 NanoRx, Inc. Policosanol nanoparticles
WO2012027159A1 (en) 2010-08-23 2012-03-01 NanoRx, Inc. Policosanol nanoparticles
GB201115633D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
CA3161908A1 (en) 2019-12-20 2021-06-24 Michael Ambuehl Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
AU2020409588A1 (en) * 2019-12-20 2022-06-09 Intervet International B.V. A pyrazole pharmaceutical composition

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO2000061189A2 (en) * 1999-04-02 2000-10-19 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20010029264A1 (en) * 1998-03-10 2001-10-11 Mcchesney-Harris Lisa L. Novel methods and compositions for delivery of taxanes
WO2003013474A1 (en) * 2001-08-09 2003-02-20 Jagotec Ag Nanoparticulate formulations of fenofibrate
US20030191179A1 (en) * 1999-10-25 2003-10-09 Supergen, Inc. Methods for administration of paclitaxel
EP1464341A1 (en) * 2003-04-03 2004-10-06 Visufarma S.R.L. Ubiquinone-containing water-soluble formulation for ophthalmic use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US20010029264A1 (en) * 1998-03-10 2001-10-11 Mcchesney-Harris Lisa L. Novel methods and compositions for delivery of taxanes
WO2000061189A2 (en) * 1999-04-02 2000-10-19 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20030191179A1 (en) * 1999-10-25 2003-10-09 Supergen, Inc. Methods for administration of paclitaxel
WO2003013474A1 (en) * 2001-08-09 2003-02-20 Jagotec Ag Nanoparticulate formulations of fenofibrate
EP1464341A1 (en) * 2003-04-03 2004-10-06 Visufarma S.R.L. Ubiquinone-containing water-soluble formulation for ophthalmic use

Also Published As

Publication number Publication date
CN101031284A (en) 2007-09-05
EP1793806A2 (en) 2007-06-13
WO2006039268A2 (en) 2006-04-13
JP2008514714A (en) 2008-05-08

Similar Documents

Publication Publication Date Title
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2009108828A3 (en) Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
WO2004043363A3 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
WO2005020913A3 (en) Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
WO2004016277A3 (en) Extraction of pharmaceutically active cannabinoids from plant materials
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
CY1113462T1 (en) DOSAGE FORM CONTENTS Pantoprazole as an Active Ingredient
WO2007047253A3 (en) Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
TW200616640A (en) Novel pharmaceutical formulations of active principles
AU2003245504A1 (en) Pharmaceutical compositions for drugs having ph-dependentsolubility
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
WO2003086293A3 (en) Pharmaceutical preparation for taste masking
WO2004105773A3 (en) Use of s1p
WO2006044805A3 (en) Less abusable pharmaceutical preparations
WO2001074790A3 (en) Novel compounds for enhancing chemotherapy
WO2003020214A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2006039268A3 (en) Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
WO2010030667A3 (en) Dosage forms for weakly ionizable compounds
WO2004047798A3 (en) Formulations of finasteride
WO2005030142A8 (en) Rifalazil formulations
WO2004064757A3 (en) Absorption enhancing agents
WO2009048940A3 (en) Diacerein pharmaceutical formulations
WO2008004100A9 (en) Therapeutic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005803721

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007534708

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580033202.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005803721

Country of ref document: EP